A Influência Do Carboidrato Na Ativação Cerebral Durante Exercício Físico

The use of carbohydrate (CH) as a nutritional supplement is related to better sports performance. Some studies have noted a relationship between consumption and brain activation influencing the performance. The objective of this study was to evaluate the influence of CH consumption in the activation of certain brain areas during exercise, performed simultaneously the acquisition of functional magnetic resonance imaging (fMRI). Ten men cyclists (32.1 ± 4.1 years, weight 76.8 ± 14.6 kg) performed a pedaling exercise protocol, with high intensity (Borg Scale), on a cycleergometer coupled to magnetic resonance (MR) and ingested 50g CH or placebo in the range of two sets of exercise. The CH ingestion showed influence on brain areas during exercise, activating areas related to decision-making (insula) and motivation (limbic system) and mainly disabling motor areas (frontal lobe) and introspection (precuneus). With the use of placebo, there was also activation of important areas in the motivation of the individual (posterior cingulate). In addition, areas associated with the initiation and maintenance of movement, located on the front lobe and cerebellum, was active. With the use of CH, areas important for maintenance of the exercise have been activated showing that supplementation can influence the brain activation during exercise to improve the sport performance.12111512

Corneal Biomechanics in Ectatic Diseases: Refractive Surgery Implications.

BACKGROUND: Ectasia development occurs due to a chronic corneal biomechanical decompensation or weakness, resulting in stromal thinning and corneal protrusion. This leads to corneal steepening, increase in astigmatism, and irregularity. In corneal refractive surgery, the detection of mild forms of ectasia pre-operatively is essential to avoid post-operative progressive ectasia, which also depends on the impact of the procedure on the cornea. METHOD: The advent of 3D tomography is proven as a significant advancement to further characterize corneal shape beyond front surface topography, which is still relevant. While screening tests for ectasia had been limited to corneal shape (geometry) assessment, clinical biomechanical assessment has been possible since the introduction of the Ocular Response Analyzer (Reichert Ophthalmic Instruments, Buffalo, USA) in 2005 and the Corvis ST (Oculus Optikgerate GmbH, Wetzlar, Germany) in 2010. Direct clinical biomechanical evaluation is recognized as paramount, especially in detection of mild ectatic cases and characterization of the susceptibility for ectasia progression for any cornea. CONCLUSIONS: The purpose of this review is to describe the current state of clinical evaluation of corneal biomechanics, focusing on the most recent advances of commercially available instruments and also on future developments, such as Brillouin microscopy.(undefined)info:eu-repo/semantics/publishedVersio

Random walks and polymers in the presence of quenched disorder

After a general introduction to the field, we describe some recent results concerning disorder effects on both `random walk models', where the random walk is a dynamical process generated by local transition rules, and on `polymer models', where each random walk trajectory representing the configuration of a polymer chain is associated to a global Boltzmann weight. For random walk models, we explain, on the specific examples of the Sinai model and of the trap model, how disorder induces anomalous diffusion, aging behaviours and Golosov localization, and how these properties can be understood via a strong disorder renormalization approach. For polymer models, we discuss the critical properties of various delocalization transitions involving random polymers. We first summarize some recent progresses in the general theory of random critical points : thermodynamic observables are not self-averaging at criticality whenever disorder is relevant, and this lack of self-averaging is directly related to the probability distribution of pseudo-critical temperatures $T_c(i,L)$ over the ensemble of samples $(i)$ of size $L$. We describe the results of this analysis for the bidimensional wetting and for the Poland-Scheraga model of DNA denaturation.Comment: 17 pages, Conference Proceedings "Mathematics and Physics", I.H.E.S., France, November 200

Predicting stroke through genetic risk functions: the CHARGE Risk Score Project.

BACKGROUND AND PURPOSE: Beyond the Framingham Stroke Risk Score, prediction of future stroke may improve with a genetic risk score (GRS) based on single-nucleotide polymorphisms associated with stroke and its risk factors. METHODS: The study includes 4 population-based cohorts with 2047 first incident strokes from 22,720 initially stroke-free European origin participants aged ≥55 years, who were followed for up to 20 years. GRSs were constructed with 324 single-nucleotide polymorphisms implicated in stroke and 9 risk factors. The association of the GRS to first incident stroke was tested using Cox regression; the GRS predictive properties were assessed with area under the curve statistics comparing the GRS with age and sex, Framingham Stroke Risk Score models, and reclassification statistics. These analyses were performed per cohort and in a meta-analysis of pooled data. Replication was sought in a case-control study of ischemic stroke. RESULTS: In the meta-analysis, adding the GRS to the Framingham Stroke Risk Score, age and sex model resulted in a significant improvement in discrimination (all stroke: Δjoint area under the curve=0.016, P=2.3×10(-6); ischemic stroke: Δjoint area under the curve=0.021, P=3.7×10(-7)), although the overall area under the curve remained low. In all the studies, there was a highly significantly improved net reclassification index (P<10(-4)). CONCLUSIONS: The single-nucleotide polymorphisms associated with stroke and its risk factors result only in a small improvement in prediction of future stroke compared with the classical epidemiological risk factors for stroke

Pleiotropy among common genetic loci identified for cardiometabolic disorders and C-reactive protein.

Pleiotropic genetic variants have independent effects on different phenotypes. C-reactive protein (CRP) is associated with several cardiometabolic phenotypes. Shared genetic backgrounds may partially underlie these associations. We conducted a genome-wide analysis to identify the shared genetic background of inflammation and cardiometabolic phenotypes using published genome-wide association studies (GWAS). We also evaluated whether the pleiotropic effects of such loci were biological or mediated in nature. First, we examined whether 283 common variants identified for 10 cardiometabolic phenotypes in GWAS are associated with CRP level. Second, we tested whether 18 variants identified for serum CRP are associated with 10 cardiometabolic phenotypes. We used a Bonferroni corrected p-value of 1.1×10-04 (0.05/463) as a threshold of significance. We evaluated the independent pleiotropic effect on both phenotypes using individual level data from the Women Genome Health Study. Evaluating the genetic overlap between inflammation and cardiometabolic phenotypes, we found 13 pleiotropic regions. Additional analyses showed that 6 regions (APOC1, HNF1A, IL6R, PPP1R3B, HNF4A and IL1F10) appeared to have a pleiotropic effect on CRP independent of the effects on the cardiometabolic phenotypes. These included loci where individuals carrying the risk allele for CRP encounter higher lipid levels and risk of type 2 diabetes. In addition, 5 regions (GCKR, PABPC4, BCL7B, FTO and TMEM18) had an effect on CRP largely mediated through the cardiometabolic phenotypes. In conclusion, our results show genetic pleiotropy among inflammation and cardiometabolic phenotypes. In addition to reverse causation, our data suggests that pleiotropic genetic variants partially underlie the association between CRP and cardiometabolic phenotypes

Quantitative Proteomic Analysis Reveals Metabolic Alterations, Calcium Dysregulation, And Increased Expression Of Extracellular Matrix Proteins In Laminin α2 Chain-deficient Muscle

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Congenital muscular dystrophy with laminin α2 chain deficiency (MDC1A) is one of the most severe forms of muscular disease and is characterized by severe muscle weakness and delayed motor milestones. The genetic basis of MDC1A is well known, yet the secondary mechanisms ultimately leading to muscle degeneration and subsequent connective tissue infiltration are not fully understood. In order to obtain new insights into the molecular mechanisms underlying MDC1A, we performed a comparative proteomic analysis of affected muscles (diaphragm and gastrocnemius) from laminin α2 chain-deficient dy3K/dy3K mice, using multidimensional protein identification technology combined with tandem mass tags. Out of the approximately 700 identified proteins, 113 and 101 proteins, respectively, were differentially expressed in the diseased gastrocnemius and diaphragm muscles compared with normal muscles. A large portion of these proteins are involved in different metabolic processes, bind calcium, or are expressed in the extracellular matrix. Our findings suggest that metabolic alterations and calcium dysregulation could be novel mechanisms that underlie MDC1A and might be targets that should be explored for therapy. Also, detailed knowledge of the composition of fibrotic tissue, rich in extracellular matrix proteins, in laminin α2 chain-deficient muscle might help in the design of future anti-fibrotic treatments. All MS data have been deposited in the ProteomeXchange with identifier PXD000978 (http://proteomecentral.proteomexchange. org/dataset/PXD000978).131130013013Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; 2014-10-6; CAPES; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; KAW2007.0118; Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Allamand, V., Guicheney, P., Merosin-deficient muscular dystrophy, autosomal recessive (mdc1a, mim#156225, lama2 gene coding for -2 chain of laminin) (2002) Eur. J. Hum. Genet., 10, pp. 91-94Helbling-Leclerc, A., Zhang, X., Topaloglu, H., Cruaud, C., Tesson, F., Weissenbach, J., Tomé, F.M.S., Guicheney, P., Mutations in the laminin -2 chain gene (lama2) cause merosin-deficient muscular dystrophy (1995) Nat. Genet., 11, pp. 216-218Voit, T., Tomé, F.S., The congenital muscular dystrophies (2004) Myology, 2, pp. 1203-1238. , (Angel, A., and Franzini-Armstrong, C., eds McGraw-Hill, New YorkIbraghimov-Beskrovnaya, O., Ervasti, J.M., Leveille, C.J., Slaughter, C.A., Sernett, S.W., Campbell, K.P., Primary structure of dystrophin-Associated glycoproteins linking dystrophin to the extracellular matrix (1992) Nature, 355, pp. 696-702Talts, J.F., Andac, Z., Gohring, W., Brancaccio, A., Timpl, R., Binding of the g domains of laminin -1 and -2 chains and perlecan to heparin, sulfatides, -dystroglycan and several extracellular matrix proteins (1999) EMBO J., 18, pp. 863-870Von Der Mark, H., Williams, I., Wendler, O., Sorokin, L., Von Der Mark, K., Pöschl, E., Alternative splice variants of -7-1 integrin selectively recognize different laminin isoforms (2002) J. Biol. Chem., 277, pp. 6012-6016Gawlik, K.I., Durbeej, M., Skeletal muscle laminin and mdc1a: Pathogenesis and treatment strategies (2011) Skelet. Muscle, 1, p. 9Han, R., Kanagawa, M., Yoshida-Moriguchi, T., Rader, E.P., Ng, R.A., Michele, D.E., Muirhead, D.E., Campbell, K.P., Basal lamina strengthens cell membrane integrity via the laminin g domain-binding motif of -dystroglycan (2009) Proc. Natl. Acad. Sci. U.S.A., 106, pp. 12573-12579Vachon, P.H., Xu, H., Liu, L., Loechel, F., Hayashi, Y., Arahata, K., Reed, J.C., Engvall, E., Integrins (-7-1) in muscle function and survival. Disrupted expression in merosin-deficient congenital muscular dystrophy (1997) J. Clin. Invest., 10, pp. 1870-1881Mayer, U., Integrins: Redundant or important players in skeletal muscle and beyond (2003) J. Biol. Chem., 279, pp. 14587-14590Gawlik, K.I., Mayer, U., Blomberg, K., Sonnenberg, A., Ekblom, P., Durbeej, M., Laminin -1 chain mediated reduction of laminin -2 chain deficient muscular dystrophy involves integrin -7-1 and dystroglycan (2006) FEBS Lett., 580, pp. 1759-1765Moll, J., Barzaghi, P., Lin, S., Bezakova, G., Lochmuller, H., Engvall, E., Muller, U., Ruegg, M.A., An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy (2001) Nature, 413, pp. 302-307Doran, P., Martin, G., Dowling, P., Jockusch, H., Ohlendieck, K., Proteome analysis of the dystrophin-deficient mdx diaphragm reveals a drastic increase in the heat shock protein cvhsp (2006) Proteomics, 6, pp. 4610-4621Gardan-Salmon, D., Dixon, J.M., Lonergan, S.M., Selsby, J.T., Proteomic assessment of the acute phase of dystrophin deficiency in mdx mice (2011) Eur. J. Appl. Physiol., 111, pp. 2763-2773Carberry, S., Zweyer, M., Swandulla, D., Ohlendieck, K., Proteomics reveals drastic increase of extracellular matrix proteins collagen and dermatopontin in the aged mdx diaphragm model of duchenne muscular dystrophy (2012) Int. J. Mol. Med., 30, pp. 229-234Ge, Y., Molloy, M.P., Chamberlain, J.S., Andrews, P.C., Proteomic analysis of mdx skeletal muscle: Great reduction of adenylate kinase 1 expression and enzymatic activity (2003) Proteomics, 3, pp. 1895-1903Guevel, L., Lavoie, J.R., Perez-Iratxeta, C., Rouger, K., Dubreil, L., Feron, M., Talon, S., Megeney, L.A., Quantitative proteomic analysis of dystrophic dog muscle (2010) J. Proteome Res., 10, pp. 2465-2449Matsumura, C.Y., Menezes De Oliveira, B., Durbeej, M., Marques, M.J., Isobaric tagging-based quantification for proteomic analysis: A comparative study of spared and affected muscles from mdx mice at the early phase of dystrophy (2013) PLoS One, 8, p. e65831Rayavarapu, S., Coley, W., Cakir, E., Jahnke, V., Takeda, S., Aoki, Y., Grodish-Dressman, H., Nagaraju, K., Identification of disease specific pathways using in vivo silac proteomics in dystrophin deficient mdx mouse (2013) Mol. Cell. Proteomics, 12, pp. 1061-1073Lewis, C., Carverry, S., Ohlendieck, K., Proteomic profiling of x-linked muscular dystrophy (2009) J. Muscle Res. Cell. Motil., 30, pp. 267-279De La Torre, C., Illa, I., Faulkner, G., Soria, L., Robles-Cedeno, R., Pereles-Dominguez-Perles, R., De Luna, N., Gallardo, E., Proteomics identification of differentially expressed proteins in the muscle of dysferlin myopathy patients (2009) Proteomics Clin. Appl., 3, pp. 486-497De Morrée, A., Hensbergen, P.J., Van Haagen, H.H., Dragan, I., Deelder, A.M., T'Hoen, P.A., Frants, R., Van Den Maarel, S.M., Proteomic analysis of the dysferlin protein complex unveils its importance for sarcolemmal maintenance and integrity (2010) PLoS One, 5, p. e13854Washburn, M., Wolters, D., Yates, J., III, Large scale analysis of the yeast proteome by multidimensional protein identification technology (2001) Nat. Biotechnol., 19, pp. 242-247Thompson, A., Schäfer, J., Kuhn, K., Kienle, S., Schwarz, J., Schmidt, G., Neumann, T., Hamon, C., Tandem mass tags: A novel quantification strategy for comparative analysis of complex protein mixtures by ms/ms (2003) Anal. Chem., 75, pp. 1895-1904Carmignac, V., Quere, R., Durbeej, M., Proteasome inhibition improves the muscle of laminin -2 chain-deficient mice (2011) Hum. Mol. Genet., 20, pp. 541-552Vizcaíno, J.A., Deutsch, E.W., Wang, R., Csordas, A., Reisinger, F., Ríos, D., Dianes, J.A., Hermjakob, H., Proteome-xchange provides globally co-ordinated proteomics data submission and dissemination (2014) Nat. Biotechnol., 32, pp. 223-226Karp, N.A., McCormick, P.S., Russell, M.R., Lilley, K.S., Experimental and statistical considerations to avoid false conclusions in proteomics studies using differential in-gel electrophoresis (2007) Mol. Cell. Proteomics, 6, pp. 1354-1364Storey, J.D., Tibshirani, R., Statistical significance for genome wide studies (2003) Proc. Natl. Acad. Sci. U.S.A., 100, pp. 9440-9445Levin, Y., The role of statistical power analysis in quantitative proteomics (2011) Proteomics, 11, pp. 2565-2567Gawlik, K., Miyagoe-Suzuki, Y., Ekblom, P., Takeda, S., Durbeej, M., Laminin -1 chain reduces muscular dystrophy in laminin -2 chain deficient mice (2004) Hum. Mol. Genet., 13, pp. 1775-1784Kline, K.G., Wu, C.C., Mudpit analysis: Application to human heart tissue (2009) Methods Mol. Biol., 528, pp. 281-293Martins De Souza, D., Oliveira, B.M., Castro-Dias, E., Winck, F.V., Horiuchi, R.S., Baldasso, P.A., Caetano, H.T., Novello, J.C., The untiring search for the most complete proteome representation: Reviewing the methods (2008) Brief Funct. Genomic. Proteomic., 7, pp. 312-321Miyagoe, Y., Hanaoka, K., Nonaka, I., Hayasaka, M., Nabeshima, Y., Arahata, K., Nabeshima, Y., Takeda, S., Laminin -2 chain-null mutant mice by targeted disruption of the lama2 gene: A new model of merosin (laminin 2)-deficient congenital muscular dystrophy (1997) FEBS Lett., 415, pp. 33-39Häger, M., Bigotti, M.G., Meszaros, R., Carmignac, V., Holmberg, J., Allamand, V., Åkerlund, M., Durbeej, M., Cib2 binds integrin -7b-1d and is reduced in laminin -2 chain-deficient muscular dystrophy (2008) J. Biol. Chem., 283, pp. 24760-247695Deconinck, N., Dan, B., Pathophysiology of duchenne muscular dystrophy: Current hypotheses (2007) Pediatr. Neurol., 26, pp. 1-7Vandebrouck, C., Martin, D., Colson-Van Schoor, M., Debaix, H., Gailly, P., Involvement of trpc in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers (2002) J. Cell Biol., 158, pp. 1089-1096Millay, D.P., Sargent, M.A., Osinska, H., Baines, C.P., Barton, E.R., Vuagniaux, G., Sweeney, H.L., Molkentin, J.D., Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy (2008) Nat. Med., 14, pp. 442-447Millay, D.P., Goonasekera, S.A., Sargent, M.A., Maillet, M., Aronow, B.J., Molkentin, J.D., Calcium influx is sufficient to induce muscular dystrophy through a trpc-dependent mechanism (2009) Proc. Natl. Acad. Sci. U.S.A., 106, pp. 19023-19028Culligan, K.G., Ohlendieck, K., Abnormal calcium handling in muscular dystrophy (2002) Basic Appl. Myol., 12, pp. 147-157Straub, V., Rafael, J.A., Chamberlain, J.S., Campbell, K.P., Animal models for muscular dystrophy show different patterns of sarcolemmal disruption (1997) J. Cell Biol., 139, pp. 375-385Gawlik, K.I., Åkerlund, M., Carmignac, V., Elamaa, H., Durbeej, M., Distinct roles for laminin globular domains in laminin -1 chain mediated rescue of murine laminin -2 chain deficiency (2010) PLoS One, 5, p. e11549Rescher, U., Gereke, V., Annexins-unique membrane binding proteins with diverse functions (2004) J. Cell Sci., 117, pp. 2631-2639Probst-Cousinm, S., Berghoff, C., Neundörfer, B., Heuss, D., Annexin expression in inflammatory myopathies (2004) Muscle Nerve, 30, pp. 102-110Jeudi, S., Wardrop, K.E., Alessi, A., Dominov, J.A., Bcl-2 inhibits the innate immune response during early pathogenesis of murine congenital muscular dystrophy (2011) PLoS One, 6, p. e22369Taniguchi, M., Kurahashi, H., Noguchi, S., Sese, J., Okinaga, T., Tsukahara, T., Guicheney, P., Toda, T., Expression profiling from fukuyama-type congenital muscular dystrophy and laminin-2 deficient congenital muscular dystrophyIs congenital muscular dystrophy a primary fibrotic disease? (2006) Biochem. Biophys. Res. Commun., 342, pp. 489-502Kuang, W., Xu, H., Vachon, P.H., Engvall, E., Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models (1998) J. Clin. Invest., 102, pp. 844-852Meinen, S., Barzaghi, P., Lin, S., Lochmuller, H., Rüegg, M.A., Linker molecules between laminins and dystroglycan ameliorate laminin-2-deficient muscular dystrophy at all disease stages (2007) J. Cell Biol., 176, pp. 979-993Doe, J.A., Wuebbles, R.D., Allred, E.T., Rooney, J.E., Elorza, M., Burkin, D.J., Transgenic overexpression of the -7 integrin reduces muscle pathology and improves viability in the dy(w) mouse model of merosin-deficient congenital muscular dystrophy type 1a (2011) J. Cell Sci., 124, pp. 2287-2297Girgenrath, M., Dominov, J.A., Kostek, C.A., Miller, J.B., Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy (2004) J. Clin. Invest., 114, pp. 1635-1639Erb, M., Meinen, S., Barzaghi, P., Sumanovski, L.T., Courdier-Fruh, I., Rüegg, M.A., Meier, T., Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-2 deficiency (2009) J. Pharmacol. Exp. Ther., 331, pp. 787-795Kumar, A., Yamauchi, J., Girgenrath, T., Girgenrath, M., Musclespecific expression of insulin-like growth factor 1 improves outcome in lama2dy-w mice, a model for congenital muscular dystrophy type 1a (2011) Hum. Mol. Genet., 20, pp. 2333-2343Carmignac, V., Svensson, M., Körner, Z., Elowsson, L., Matsumura, C., Gawlik, K., Allamand, V., Durbeej, M., Autophagy is increased in laminin -2 chain-deficient muscle and inhibition improves muscle morphology in a mouse model of mdc1a (2011) Hum. Mol. Genet., 20, pp. 4891-4902Rooney, J.E., Knapp, J.R., Hodges, B.L., Wuebbles, R.D., Burkin, D.J., Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy (2011) Am. J. Pathol., 180, pp. 1593-1602Elbaz, M., Yanay, N., Aga-Mizrachi, S., Brunschwig, Z., Kassis, I., Ettinger, K., Barak, V., Nevo, Y., Losartan, a therapeutic candidate in congenital muscular dystrophy: Studies in the dy2j/dy2j mouse (2012) Ann. Neurol., 71, pp. 699-708Meinen, S., Lin, S., Rüegg, M.A., Angiotensin ii type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-2-deficient congenital muscular dystrophy (mdc1a) (2012) Skelet. Muscle, 2, p. 18Turk, R., Sterrenburg, E., Van Der Wees, C.G., De Meijer, E.J., De Menezes, R.X., Groh, S., Campbell, K.P., Hoen, T.P.A., Common pathological mechanisms in mouse models for muscular dystrophies (2006) FASEB J., 20, pp. 127-129Chen, Y.W., Zhao, P., Borup, R., Hoffman, E.P., Expression profiling in the muscular dystrophies: Identification of novel aspects of molecular pathophysiology (2000) J. Cell Biol., 151, pp. 1321-1336Chinet, A.E., Even, P.C., Decrouy, A., Dystrophin-dependent efficiency of metabolic pathways in mouse skeletal muscles (1994) Experientia, 59, pp. 602-605Even, P.C., Decrouy, A., Chinet, A., Defective regulation of energy metabolism in the mdx-mouse skeletal muscles (1994) Biochem. J., 304, pp. 649-654Groh, S., Zong, H., Goddeeris, M.M., Lebakken, C.S., Venzke, D., Pessin, J.E., Campbell, K.P., Sarcoglycan complex: Implications for metabolic defects in muscular dystrophies (2009) J. Biol. Chem., 284, pp. 19178-19182Onopiuk, M., Brutkowski, W., Wierzbicka, K., Wojciechowska, S., Szczepanowska, J., Fronk, J., Lochmuller, H., Zablocki, K., (2009) Biochem. Biophys. Res. Commun., 386, pp. 463-466Le Borgne, F., Guyot, S., Logerot, M., Beney, L., Gervais, P., Demarquoy, J., Exploration of lipid metabolism in relation with plasma membrane properties of duchenne muscular dystrophy cells: Influence of l-carnitine (2012) PLoS One, 7, p. e49346Matsumura, C.Y., Pertille, A., Albuquerge, T.C., Santo Neto, H., Marques, M.J., Diltiazem and verapamil protect dystrophin-deficient muscle fibers of mdx mice from degeneration: A potential role in calcium buffering and sarcolemmal stability (2009) Muscle Nerve, 39, pp. 167-176Jørgensen, L.H., Blain, A., Greally, E., Lavala, S.H., Blamire, A.M., Davison, B.J., Brinkmeier, H., Lochmüller, H., Long-term blocking of calcium channels in mdx mice results in differential effects on heart and skeletal muscle (2011) Am. J. Pathol., 178, pp. 273-283Goonasekera, S.A., Lam, C.K., Millay, D.P., Sargent, M.A., Hajjar, R.J., Kranias, E.G., Molkentin, J.D., Mitigation of muscular dystrophy in mice by serca overexpression in skeletal muscle (2011) J. Clin. Invest., 121, pp. 1044-1052Horiuchi, K., Amizuka, N., Takeshita, S., Takamatsu, H., Katsuura, M., Ozawa, H., Toyama, Y., Kudo, A., Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor (1999) J. Bone Miner. Res., 14, pp. 1239-1249Lorts, A., Schwanekamp, J.A., Baudino, T.A., McNally, E.M., Molkentin, J.D., Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor- pathway (2012) Proc. Natl. Acad. Sci. U.S.A., 109, pp. 10978-10983Ting, L., Rad, R., Gygi, S.P., Haas, W., Ms3 eliminates ratio distortion in isobaric multiplexed quantitative proteomics (2011) Nat. Methods, 8, pp. 937-940Christoforou, A., Lilley, K.S., Taming the isobaric tagging elephant in the rooms in quantitative proteomics (2011) Nat. Methods, 8, pp. 911-91

PAMOP Project: computations in support of experiments and astrophysical applications

Our computation effort is primarily concentrated on support of current and future measurements being carried out at various synchrotron radiation facilities around the globe, and photodissociation computations for astrophysical applications. In our work we solve the Schr\"odinger or Dirac equation for the appropriate collision problem using the R-matrix or R-matrix with pseudo-states approach from first principles. The time dependent close-coupling (TDCC) method is also used in our work. A brief summary of the methodology and ongoing developments implemented in the R-matrix suite of Breit-Pauli and Dirac-Atomic R-matrix codes (DARC) is presented.Comment: 17 pages, 10 figures: chapter in the book, High Performance Computing in Science and Engineering'16, edited by W. E. Nagel, D. B. Kr\"oner, and M. Reich (Springer, New York and Berlin, 2017